Literature DB >> 17283148

In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice.

Hiroshi Tada1, Hideo Higuchi, Tomonobu M Wanatabe, Noriaki Ohuchi.   

Abstract

Studies with tracking of single nanoparticles are providing new insights into the interactions and processes involved in the transport of drug carriers in living mice. Here, we report the tracking of a single particle quantum dot (Qdot) conjugated with tumor-targeting antibody in tumors of living mice using a dorsal skinfold chamber and a high-speed confocal microscope with a high-sensitivity camera. Qdot labeled with the monoclonal anti-HER2 antibody was injected into mice with HER2-overexpressing breast cancer to analyze the molecular processes of its mechanistic delivery to the tumor. Movement of single complexes of the Qdot-antibody could be clearly observed at 30 frames/s inside the tumor through a dorsal skinfold chamber. We successfully identified six processes of delivery: initially in the circulation within a blood vessel, during extravasation, in the extracelullar region, binding to HER2 on the cell membrane, moving from the cell membrane to the perinuclear region, and in the perinuclear region. The six processes were quantitatively analyzed to understand the rate-limiting constraints on Qdot-antibody delivery. The movement of the complexes at each stage was "stop-and-go." The image analysis of the delivery processes of single particles in vivo provides valuable information on antibody-conjugated therapeutic nanoparticles, which will be useful in increasing therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283148     DOI: 10.1158/0008-5472.CAN-06-1185

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  104 in total

Review 1.  Biocompatible quantum dots for biological applications.

Authors:  Sandra J Rosenthal; Jerry C Chang; Oleg Kovtun; James R McBride; Ian D Tomlinson
Journal:  Chem Biol       Date:  2011-01-28

2.  Modification of microneedles using inkjet printing.

Authors:  R D Boehm; P R Miller; S L Hayes; N A Monteiro-Riviere; R J Narayan
Journal:  AIP Adv       Date:  2011-06-10       Impact factor: 1.548

Review 3.  Inorganic nanoparticle-based contrast agents for molecular imaging.

Authors:  Eun Chul Cho; Charles Glaus; Jingyi Chen; Michael J Welch; Younan Xia
Journal:  Trends Mol Med       Date:  2010-11-10       Impact factor: 11.951

Review 4.  Detecting and treating cancer with nanotechnology.

Authors:  Keith B Hartman; Lon J Wilson; Michael G Rosenblum
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 5.  Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.

Authors:  Prabhani U Atukorale; Gil Covarrubias; Lisa Bauer; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2016-09-15       Impact factor: 15.470

Review 6.  Quantum dot-based nanoprobes for in vivo targeted imaging.

Authors:  Y Zhu; H Hong; Z P Xu; Z Li; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 7.  Antibody-based imaging of HER-2: moving into the clinic.

Authors:  R E Wang; Y Zhang; L Tian; W Cai; J Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

8.  Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge.

Authors:  Jorina Geys; Abderrahim Nemmar; Erik Verbeken; Erik Smolders; Monica Ratoi; Marc F Hoylaerts; Benoit Nemery; Peter H M Hoet
Journal:  Environ Health Perspect       Date:  2008-07-18       Impact factor: 9.031

9.  Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature.

Authors:  Bryan Ronain Smith; Zhen Cheng; Abhijit De; Ai Leen Koh; Robert Sinclair; Sanjiv Sam Gambhir
Journal:  Nano Lett       Date:  2008-04-04       Impact factor: 11.189

Review 10.  Nanotechnology applications in surgical oncology.

Authors:  Sunil Singhal; Shuming Nie; May D Wang
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.